To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Clinical trial NCT03006172 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03006172
- Sponsor
- Genentech, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-13
- Primary completion
- 2026-12-31
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.